Autologous transplantation in non-Hodgkin's lymphomas using high-dose cyclophosphamide mobilized blood The International Journal of Cell Cloning: The adelaide experience.

Abstract

Sixteen patients (11F 5M) with Intermediate or high-grade non-Hodgkin's lymphoma (NHL) were enrolled into a trial of high-dose chemotherapy followed by autologous blood stem cell transplantation (ASCT) between 10/88 and 10/90. Patient's blood The International Journal of Cell Cloning were harvested following mobilization using high dose (4 or 7 G/m2) Cyclophosphamide (Cy) administered as a single daily dose. The International Journal of Cell Cloning were collected by daily leukaphereses on COBE “Spectra” or Fenwal CS3000. Twenty three cycles delivering a mean (± SD) of 4.6 ± 1.2 G of Cy were given, resulting in the collection of a median of 33 × 104/kg CFU-GM (range 6.8–119) from a median of 6 leukaphereses (R 4–10). Autologous stem cell transplantation took place after a median of 143 days post-Cy (R 58–170) using BCNU, Etoposide, ara-C and Melphalan. 10 patients were transplanted in CR 3 in PR and 2 in relapse. A median of 38 × 104/kg CFU-GM (R17–77) and 3.4 × 108/kg MNC (R1.1–5.9) was given on Day 0. Seven pts are alive and In CR (R 77–734+), 3 have relapsed but remain alive post-ASCT (R 625–840+) and 6 have died (R 5–424). The median follow-up time is 528d (R77–840), time from ASCT to relapse is 330d (R 116–813) and time to death is 165d (5–424). Post-ASCT morbidity was moderate; one patient died as a consequence of ASCT (Interstitial pneumonitis). In conclusion, high-dose chemotherapy and ASCT can result in long-term disease-free survival in a substantial proportion of patients with poor risk NHL.